openPR Logo
Press release

Alzheimer's Diagnostics And Therapeutics Market Set to Reach US$ 14.8 Billion by 2033 with Strong 8.4% CAGR

08-28-2023 04:40 PM CET | Health & Medicine

Press release from: Future Market Insights Inc.

Alzheimer's Diagnostics And Therapeutics Market

Alzheimer's Diagnostics And Therapeutics Market

As per Future Market Insights' latest industry analysis, the valuation for the global Alzheimer's Diagnostics And Therapeutics Market is estimated to be around US$ 6.1 Billion in 2023 and is projected to exhibit a CAGR of 8.4% over the forecast period, with an estimated valuation of US$ 14.8 Billion in 2033.

Many research activities regarding the development of diagnostic technologies are going on in the world for the treatment of Alzheimer's. In addition to the traditional medical and neurological processes, new technologies are assisting in the diagnosis and treatment of Alzheimer's disease. New diagnostic criteria are helping to identify validated diagnostic biomarkers.

Click here to claim your report with captivating visuals. @
https://www.futuremarketinsights.com/reports/sample/rep-gb-17049

Many new technologies are being used to monitor Alzheimer's disease and to detect its progression over time, which guides individuals in maintaining and tracking their activities. Much new research has emerged that investigates cloud-based solutions to dementia and Alzheimer's disease, including care, treatment, and diagnosis. There are several drugs in the pipeline for the treatment of Alzheimer's disease, which is expected to receive regulatory approvals in the coming years. For instance, Biogen's Aducanumab received FDA approval in 2021, making it the first new drug for Alzheimer's disease in almost 20 years. Such pipeline developments could drive the growth of the Alzheimer's therapeutics market.

Advancements in imaging technologies such as positron emission tomography (PET) and magnetic resonance imaging (MRI) have allowed for improved detection of structural and functional changes in the brain associated with Alzheimer's disease. Several new drug therapies have emerged in recent years, including monoclonal antibodies that target beta-amyloid and tau proteins. These drugs have shown promise in slowing or halting the progression of the disease. Gene therapy is a promising approach to treating Alzheimer's disease by delivering therapeutic genes to affected areas of the brain. While still in the experimental stages, this approach has shown potential in preclinical studies.

Overall, these advancements in diagnostics and therapeutics are helping to improve the understanding of Alzheimer's disease and develop more effective treatments for this devastating condition.

Moreover, the Alzheimer's diagnostics and therapeutics market is expected to grow in the coming years due to the increasing aging population, advancements in diagnostics and therapeutics, pipeline developments, rising healthcare spending, and technological advancements.

Key Takeaways from the Market Study:

Diagnostics is the leading segment by product, and held a 1% market value share in 2022, owing to new technologies that are being used to monitor Alzheimer's disease and to detect its progression.
By distribution channel, institutional sales are leading in the global Alzheimer's diagnostics and therapeutics market, and are expected to continue to do so with a projected CAGR of 3% during the forecasted years.
North America is considered the leading region with a value share of 0% in 2022, as there is a growing number of people in the U.S. who are at risk of developing Alzheimer's disease.

Elevate your awareness with our enlightening methodology insights. @
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-17049

Market Competition:

Eisai Inc., AlzeCure Pharma, TrueBinding, Inc., and Cognition Therapeutics are some of the key players who are involved in the clinical trials, among others in the study of Alzheimer's diagnostics and therapeutics. Many companies strategize to acquire any competitor or company that generates less revenue. The business alliance aims to support the distribution of the product portfolio across developed regions and emerging players are focusing on expanding to strengthen their product portfolio.

-In March 2022, AbbVie acquired Syndesi Therapeutics to expand its Neuroscience Portfolio.
-In February 2022, Janssen and partnered company AC Immune found that at an early stage, the Alzheimer's vaccine activates the induction of antibodies that attack tau, a type of protein.

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on the Alzheimer's diagnostics and therapeutics market in its latest study, presenting a historical demand assessment of 2012 - 2022 and projections for 2023 - 2033. The Alzheimer's diagnostics and therapeutics market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader

The research study is based on the product - {Therapeutics (cholinesterase inhibitors, NMDA receptor antagonists, and manufactured combination), and Diagnostics (lumbar diagnostics test, CT Scan, MRI, EEG, and PET scan)}, by distribution channel {institutional sales (hospitals, specialty clinics, and diagnostic centers), and retail sales {retail pharmacies, drug stores, and online pharmacies)}, and by seven key regions of the world.

Key Market Segments Covered in Alzheimer's diagnostics and therapeutics Industry Research

By Product:

>Therapeutics
-Cholinesterase Inhibitors
-NMDA Receptor Antagonists
-Manufactured Combination
>Diagnostics
-Lumbar Diagnostics Test
-CT Scan
-MRI
-EEG
-PET scan

By Distribution Channel:

>Institutional Sales
-Hospitals
-Specialty Clinics
-Diagnostic Centers
>Retail Sales
-Retail Pharmacies
-Drug Stores
-Online Pharmacies

By Region:

-North America
-Latin America
-Europe
-South Asia
-East Asia
-Oceania
-Middle East and Africa (MEA)

Contact Us:          

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Read the Complete Research Now @
https://www.futuremarketinsights.com/reports/alzheimers-diagnostics-and-therapeutics-market

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, Stevie Award - recipient market research organization, and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel, and End Use over the next 10 years.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Alzheimer's Diagnostics And Therapeutics Market Set to Reach US$ 14.8 Billion by 2033 with Strong 8.4% CAGR here

News-ID: 3184957 • Views:

More Releases from Future Market Insights Inc.

Oil & Gas Electrification Market Projected to Surge to USD 5 Billion by 2035, Driven by Decarbonization, Renewable Energy Integration, and Digital Advancements
Oil & Gas Electrification Market Projected to Surge to USD 5 Billion by 2035, Dr …
The global oil & gas electrification market is set for remarkable expansion, with an estimated value of USD 2.1 billion in 2025 and a projected surge to USD 5.0 billion by 2035. This growth trajectory reflects a compound annual growth rate (CAGR) of 9.1%, driven by increasing investments in sustainable electrification technologies and heightened regulatory pressures aimed at reducing carbon emissions across the industry. As the oil and gas sector faces
Global Glassware Market to Reach USD 15.4 Billion by 2035, Driven by Rising Demand for Premium, Sustainable Products and Innovation in Design
Global Glassware Market to Reach USD 15.4 Billion by 2035, Driven by Rising Dema …
The global glassware market is on track to experience steady growth over the next decade, with a projected compound annual growth rate (CAGR) of 5.9% from 2025 to 2035. Valued at USD 8.7 billion in 2025, the market is expected to reach an impressive USD 15.4 billion by 2035. This growth is primarily attributed to the rising demand for high-quality, aesthetically appealing, and sustainable glassware products, particularly in the hospitality,
nduction Hob Market Expected to Reach USD 58.2 Million by 2035, Driven by Growing Demand for Energy-Efficient Cooking Solutions
nduction Hob Market Expected to Reach USD 58.2 Million by 2035, Driven by Growin …
The global Induction Hob Market is set to experience significant growth, with an estimated market value of USD 23.5 million in 2025 and a projected rise to USD 58.2 million by 2035, marking a compound annual growth rate (CAGR) of 9.5% over the forecast period. As consumers increasingly shift toward energy-efficient and technologically advanced cooking solutions, the induction hob sector is poised to benefit from a growing preference for safe,
Automatic Bottle Opener Market to Reach USD 1.43 Billion by 2035, Driven by Consumer Demand for Convenience and Smart Kitchen Solutions
Automatic Bottle Opener Market to Reach USD 1.43 Billion by 2035, Driven by Cons …
The automatic bottle opener market is experiencing significant growth and is forecasted to reach USD 1.43 billion by 2035, up from USD 756.5 million in 2025. With a compound annual growth rate (CAGR) of 6.6%, the market is expected to evolve significantly over the next decade, propelled by the increasing popularity of automated home appliances and smart kitchen tools. This surge is driven by the growing demand for convenient, easy-to-use solutions

All 5 Releases


More Releases for Alzheimer

Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion. Data Bridge
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants. From the perspective of market dynamics, this report explores the factors driving the growth
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports. Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as